Investors are closely watching Eli Lilly & Company (LLY) as the pharmaceutical giant prepares to release its fiscal third-quarter results later this week. Analysts are anticipating strong performance driven by the continued success of Lilly's blockbuster drugs, particularly its insulin portfolio. However, there are also concerns about potential cha